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creasing despite persistently ongoing research. Despite 
conventional therapies such as surgical resection, radio-
therapy and chemotherapy, most patients suffer from 
cancer recurrence. As the malignant tumor is constituted 
by a morphologically and functionally heterogeneous 
population of cells, and the majority of cells are destined 
to differentiate or transit-amplify, a minor cell popula-
tion is defined as a group of undifferentiated cells with 
the ability (i) to duplicate themselves and self-renew, (ii) 
to regenerate a phenocopy of the original tumor and drive 
neoplastic proliferation, when transplanted into the non-
obese diabetic/severe combined immunodeficient mouse, 
and (iii) to differentiate to some degree into more mature 
non-stem-cell cancer lineages. These cells referred to as 
cancer stem cells (CSCs) received increasing attention as 
novel targets for cancer therapy, in particular as emerging 
evidence indicates that CSCs are substantially associated 
with tumor initiation, angiogenesis, cancer maintenance 
and metastasis  [1, 2] . Actually, the clinically most relevant 
cancer cells are probably not those that engraft immuno-
deficient mice, but rather those that are responsible for 
cancer relapse. Accordingly, even if every cancer cell pos-
sesses tumorigenic potential, the more clinically relevant 
question is probably whether any cell can also be respon-
sible for relapse or only a discrete cell subset  [3] . Even 
more challenging is the established tight interaction be-
tween a tumor and its environment  [4] , which can trans-
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 Abstract
 The existence of cancer stem cells (CSCs) is receiving increas-
ing interest particularly due to its potential ability to enter 
clinical routine. Rapid advances in the CSC field have pro-
vided evidence for the development of more reliable anti-
cancer therapies in the future. CSCs typically only constitute 
a small fraction of the total tumor burden; however, they har-
bor self-renewal capacity and appear to be relatively re-
sistant to conventional therapies. Recent therapeutic ap-
proaches aim to eliminate or differentiate CSCs or to disrupt 
the niches in which they reside. Better understanding of the 
biological characteristics of CSCs as well as improved pre-
clinical and clinical trials targeting CSCs may revolutionize 
the treatment of many cancers.  Copyright © 2012 S. Karger AG, Basel
 Introduction
 During the past decades, researchers keenly endeav-
ored to develop effective anticancer therapies. However, 
the incidence and the mortality of cancers are still in-
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fer nonstem cells into CSCs, since the CSC phenotype is 
more alternating than anticipated and strongly regulated 
by the tumor cell environment  [5] . In any case, of greatest 
clinical implication is the development of an effective 
treatment regimen that prevents survival, self-renewal 
and differentiation of CSCs and disturbs the microenvi-
ronmental niche of CSCs without damaging normal stem 
cells. In this premise, we highlight the latest clinical de-
velopments in CSCs targeting therapy and discuss the 
stumbling blocks which stand on the way to our expected 
target therapy goal.
 The Dandelion Phenomenon
 The therapy of chronic myeloid leukemia (CML) has 
evolved significantly over the past two decades. Before 
the availability of imatinib,   -interferon was used in high 
doses and was associated with the achievement of hema-
tological and even molecular remission in individuals 
with CML; however, significant toxicities were frequent-
ly encountered including depression and neurological 
disturbances. Imatinib was found to be superior for 
achieving cytogenetic and molecular responses and pro-
longing event-free survival as compared to   -interferon 
 [6, 7] . However, the long-term follow-up of participants 
continues to show that not all patients remain in long-
term molecular remission with imatinib therapy and that 
as many as 25–30% of the patients become resistant  [7, 8] . 
CML patients who achieve the best responses to imatinib 
can relapse quickly when the drug is discontinued  [9–12] 
or even progress while remaining on the drug  [12] .
 This phenomenon where a therapy eliminates most of 
the tumor bulk but spares the CSCs could be considered 
analogous to mowing dandelions; although this will elim-
inate the visible portion of the weeds, the unseen roots 
also need to be addressed to prevent regrowth  [3, 13–15] . 
In contrast, a treatment addressing CSCs would be com-
parable to attacking just the root of the dandelion; al-
though this therapy has no immediate discernible effect 
on the weeds, over time the weeds should eventually with-
er and die when the roots have been eliminated  [3, 13–15] .
 The dandelion phenomenon can be applied in many 
studies, since the achievement of a complete response and 
total eradication of all macroscopic diseases has not been 
associated with increased overall survival as compared to 
patients achieving only partial remission following treat-
ment. For example, several large randomized studies us-
ing combination chemotherapy in pancreatic adenocar-
cinoma have demonstrated improved rates of tumor re-
sponse but only negligible or no improvements in overall 
survival  [16] . CSCs might be accountable for this discrep-
ancy in many malignancies as tumor response primarily 
reflects short-term changes regarding the bulk of tumor 
cells, whereas long-term outcome represented by disease 
relapse based on local or systemic progression and overall 
survival might be attributed to CSCs  [16] .
 Clinical Relevance of CSCs
 Due to the common property of CSCs including self-
renewal capacity, tumorigenicity, proliferative capacity 
and resistance to standard antitumor therapy, it is obvi-
ous to posit that metastasis formation as well as cancer 
relapse are closely associated with CSCs  [17] .
 A number of recent researches have examined wheth-
er CSCs can serve as predictive biomarkers and have in-
cluded studies examining the association between the 
frequency of CSCs, the expression of CSC-specific gene 
signatures and the qualification of functional CSC prop-
erties with clinical outcome  [16, 18] . In human acute my-
eloid leukemia, a link between leukemic stem cell (LSC) 
burden and clinical behavior by showing that undifferen-
tiated acute myeloid leukemia (FAB subtype M0) has a 
higher frequency of LSCs and a poorer prognosis than 
other FAB subtypes have suggested  [18–20] . A more re-
cent study directly addressed the relationship between 
LSC frequency and clinical outcome, demonstrating that 
the frequency of LSCs at the time of diagnosis correlates 
with several clinical endpoints, including overall surviv-
al, disease-free and relapse-free survival  [18] .
 CSCs also correlate with the prognosis of gliomas. A 
recent study found high levels of the neural progenitor 
cell marker nestin in more aggressive high-grade glio-
mas. High-grade gliomas also coexpressed high levels of 
cysteine  [21] and cathepsins B and L, two further markers 
for invasion. A coexpression of both markers indicated a 
poorer prognosis and a significantly shorter survival of 
glioma patients  [22] . By Cox regression analysis, nestin 
was shown to be a stronger prognostic marker than ca-
thepsins B and L  [21] . In addition, in breast cancer the 
prognostic value of CSC markers in the clinic has begun 
to emerge. Tumors mainly composed of CD44+CD24–
PROCR+ cells presented with a worse clinical outcome 
than tumors with a CD44–CD24+ signature  [23] . Re-
cently, Liu et al.  [24] compared a 186-gene-containing
expression profile of CD44+CD24–/low putative breast 
CSCs to that of normal breast epithelium and found a 
statistically significant association between the gene sig-
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nature in both overall and metastasis-free survival in ad-
dition to established clinical and pathological variables. 
This unique gene signature was then used to stratify pa-
tients into high-risk (10-year survival of 81%) and low-
risk (10-year survival of 57%) patients in combination 
with prognostic criteria of the National Institutes of 
Health. The gene signature was further associated with 
the prognosis in medulloblastoma, lung cancer and pros-
tate cancer  [22, 24] . In summary, the genetic profile of 
CSCs may serve as useful predictor for clinical outcome.
 CSCs Are Resistant to Conventional Anticancer 
Therapy
 Current anticancer therapy strategies mainly include 
chemotherapy, radiotherapy and surgery; so far these 
therapeutic strategies either alone or in combination fail 
to eradicate CSC clones and instead favor the expansion 
of the CSC pool and/or select for resistant CSC clones, 
thus leading to a fatal outcome of the disease  [23] .
 Chemotherapy
 Most chemotherapies eradicate a substantial part of 
the tumor cells; however, CSCs which stay dormant for 
long periods during therapy will eventually reenter the 
cell cycle and recapitulate tumor regrowth since their 
ability of chemoresistance is increasing under chemo-
therapy  [25] . There is quite a lot of evidence for enhanced 
chemoresistance of CSCs: Liu et al.  [26] first demonstrat-
ed that CD133+ brain tumor stem cells disclosed a sur-
vival advantage to chemotherapeutic agents such as te-
mozolomide, carboplatin, paclitaxel and etoposide com-
pared to autologous CD133– cells  [25] . CD133 has proven 
to be a marker for neuroepithelial, hematopoietic, breast 
and endothelial progenitor cells  [23, 27–29] . Further-
more, studies in patients with CML showed that CML 
stem cells are resistant to imatinib treatment indepen-
dently from the existence of resistance-associated muta-
tions in the BCR-ABL gene  [5, 30, 31] . Similarly, in gas-
trointestinal stromal tumors CSCs seem to be resistant to 
imatinib  [32] . In addition, in colorectal cancer after con-
ventional chemotherapy with oxaliplatin, irinotecan and 
fluorouracil, the CSC population is enlarged and more 
resistant to chemotherapy than non-CSCs in xenograft 
mouse models  [5, 33–35] . Comparably, Szotek et al.  [36] 
 showed that CSCs of ovarian cancer could not be inhib-
ited by doxorubicin unlike non-CSCs.
 There are several properties that contribute to the che-
moresistance of CSCs as shown below.
 Quiescent Phenotype
 Conventional chemotherapies largely rely on cycling 
cells in order to cause lethal cellular damage; in contrast, 
CSCs stay dormant during or after the treatment for a 
long time until reentry of the cell cycle to stimulate tumor 
cell proliferation  [1] .
 Antiapoptosis
 Based on the expression of antiapoptotic proteins such 
as BCL-2 some self-renewal pathways such as transform-
ing growth factor   , Wnt/  -catenin or BMI-1 are acti-
vated and lead to enhanced capability to repair DNA 
damage after genotoxic stress or activation of autocrine 
loops through the production of growth factors like epi-
dermal growth factor  [37] .
 Expression of Certain Drug Efflux Pumps
 Typical drug efflux proteins such as ABCC1, ABCG2 
or MDR1, which are the principal mediators of multidrug 
resistance identified so far, are expressed on CSCs  [37] . 
Multidrug resistance-associated proteins (ABCC sub-
family) are members of the ATP-binding cassette (ABC) 
superfamily of transport proteins and act as cellular ef-
flux transporters for a wide variety of substrates, in par-
ticular glutathione, glucuronide and sulfate conjugates
of diverse compounds. Together with P-glycoprotein 
(MDR1; ABCB1) and breast cancer resistance protein 
(ABCG2), the multidrug resistance-associated proteins 
are highly important as cellular defense against toxicants 
and confer multixenobiotic resistance  [38] . In the breast 
cancer cell lines MCF-7 and Cal-51, recently side popula-
tion cells expressing ABCG2 transporter properties have 
been isolated. Purified MCF-7 side population cells fur-
ther demonstrated an increased ability to colonize the 
mouse mammary gland as compared to non-side-popu-
lation MCF-7 cells  [4] . In metastatic human pancreatic 
cancer cells (L3.6pl), side population cells have been iden-
tified as potential CSCs being responsible for gemcitabine 
resistance  [39] . These cells also displayed the capacity of 
self-renewal, differentiation, induction of aggressive tu-
mor growth, as well as high rates of metastasis [unpubl. 
data]. In summary, the resistance properties of CSCs an-
alyzed above provide some potential targets for anti-CSC 
therapy.
 Radiotherapy
 Recent investigations on CSC-associated resistance to 
radiotherapy are mainly related to breast cancer and glio-
blastoma multiforme. In glioblastoma multiforme, scien-
tists showed that CD133+ CSCs contributed to glioma ra-
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dioresistance through preferential activation of the high-
ly efficient DNA damage repair pathway, less apoptosis by 
significantly induced checkpoint kinases and an increase 
in DNA repair capacity compared to CD133– tumor cells 
 [25, 40] . In breast cancer, progenitor cells in the mam-
mary gland are more resistant to clinically relevant doses 
of radiation than nonprogenitor cells  [41] . Diehn et al. 
[42] demonstrated that reduced levels of reactive oxygen 
species are associated with radioresistance in CSCs. In 
addition, Chen et al. [43] identified that the Wnt/  -
catenin pathway mediates radiation resistance of progen-
itor cells in an immortalized mammary gland cell line.
 Moreover, the tumor microenvironment is substan-
tially involved in the distribution of CSCs within the
tumour mass and the mediation of the radiotherapy
response. Recent research reports identified hypoxia as 
crucial for the expansion and maintenance of CSCs in 
different tumor entities  [37, 44, 45] . Selective therapy of 
hypoxic areas within the tumor would eradicate CSC 
niches. Modern radiotherapy techniques might allow to 
accurately deliver selective doses of radiotherapy to hyp-
oxic areas of the tumor instead of an inhomogeneous 
dose distribution within the tumor mass  [37, 46] .
 Surgery
 Although surgery is frequently still the gold standard 
of curative treatment and has a broad indication for many 
solid neoplasms, most patients ultimately suffer from lo-
cal recurrence or systemic relapse due to metastasis based 
on minimal residual disease which is enriched for CSCs. 
One example is glioblastoma multiforme, the most malig-
nant and aggressive type of brain tumor. At present, even 
the combination of surgical resection, advanced chemo-
therapy as well as radiotherapy remains a palliative ther-
apy with an average recurrence-free survival of only 6.9 
months and a 5-year survival rate of less than 5%  [1, 47] .
 How to Target CSCs More Accurately?
 Based on the previous knowledge of the biological 
character of CSCs one can conclude that CSC targeting 
therapy ( table  1 ) should be designed on the following 
principles: eliminating CSCs by either killing or differen-
tiating them, and/or disrupting the niches and microen-
vironments in which the CSCs reside  [17] . Efficient erad-
ication of CSCs may require the combined ablation of 
CSCs themselves and their niches. Regarding preferential 
microenvironments of CSCs, controversial reports exist: 
there are perivascular as well as hypoxic niches  [17] .
 Identification of CSC Markers
 CSCs have been isolated and purified from cancers of 
the breast, brain, thyroid, cervix, lung, blood (leukemia), 
skin (melanoma), organs of the gastrointestinal and re-
productive tracts, and the retina using cell surface mol-
ecules as markers  [48] .
 Since CSCs share the same or similar cell markers with 
normal stem cells, CSC-targeted therapy will eventually 
damage normal stem cells during the treatment, so it is 
substantial to identify more specific CSC markers.
 More recently, advanced techniques such as signal se-
quence trap (SST) PCR screening methods have been de-
veloped to identify a leukemia-specific stem cell marker 
(CD96)  [49] . The SST PCR screening method possessed 
the ability to redirect a constitutively active mutant of a 
cytokine receptor to the cell membrane detecting mRNAs 
that contain signal sequences on cDNA fragments and 
thereby inducing interleukin-3-independent growth of a 
mouse B cell line Ba/F3  [50] . Hosen et al. [49] identified 
with SST PCR CD96 which was much more highly ex-
pressed in different CD34+CD38– acute myeloid leuke-
mia blasts. The implication is that CSCs can be primarily 
enriched using currently identified surface molecules in 
conjunction with a subsequent approach such as SST that 
can be assembled for additional marker identification 
 [22] .
 It has already been shown that proteins such as nodal 
and activin are expressed during embryonic development 
of the mesoderm formation and the left-right axis speci-
fication  [51] . Recently, researchers found that knockdown 
or pharmacological inhibition of the nodal/activin recep-
tor Alk4/7 in CD133+/CD44+ pancreatic CSCs virtually 
abrogated their self-renewal capacity as well as in vivo 
tumorigenicity, and reversed the resistance of orthotopi-
cally engrafted CSCs to gemcitabine. The additional ap-
plication of a stroma-targeting hedgehog pathway inhib-
itor enhanced the delivery of the nodal/activin inhibitor 
and resulted in long-term progression-free survival of the 
animals. Therefore, inhibition of the Alk4/7 pathway, if 
combined with inhibition of the hedgehog pathway and 
gemcitabine, provides a therapeutic strategy for targeting 
CD133+/CD44+ pancreatic CSCs  [51] . Further identifica-
tion of new CSC surface markers may provide additional 
targets for the design of anti-CSC therapy  [52] .
 Targeting Specific Molecular Pathways in CSCs
 Normal and malignant stem cells share important 
functional pathways; thus, it is essential to develop CSC-
selective therapies without potential side effects address-
ing normal stem cell function. Those pathways include 
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Wnt/  -catenin, hedgehog, notch, Hox family members, 
BMI-1, PTEN and nodal/activin  [18, 53–55] . For example, 
cyclopamine as an antagonist of the hedgehog coreceptor 
SMO significantly eliminated CSCs in CML and im-
paired the growth of imatinib-resistant mouse and hu-
man CML cells  [56] . In medulloblastoma, the inhibition 
of notch signaling through   -secretase inhibitors sub-
stantially reduced the CD133+ brain CSC population 
 [57] . Meanwhile, inhibition of notch using small mole-
cule inhibitors of   -secretase is currently evaluated in 
phase I and II clinical trials for glioblastoma  [58] .
 The difference between CSCs and normal stem cells 
regarding telomere length and telomerase activity may 
provide another therapeutic option against CSCs. Nor-
mal stem cells require telomerase to prevent telomere 
shortening leading to replicative senescence. However, 
even in the absence of telomerase, normal stem cells can 
maintain their replicative capacity for some period of 
time because of their relatively long telomeres. In con-
trast, constitutive telomerase activity is absolutely re-
quired for the maintenance and growth of most malig-
nancies in order to stabilize short telomeres typically for 
 Table 1.  Selection of methods used for CSC-targeting therapy
 Target type  Specific target  Characteristics  Ref. 
 Cell
 markers 
 CD24+CD44+ESA+  Pancreatic CSCs, expression level is elevated during tumorigenesis  25, 72 
 CD44+CD24–ESA+  Breast CSCs  73 
 EpCAM high CD44+CD166+  Colorectal cancer  74 
 CD34+CD38–  AML, broad use as a target for chemotherapy  75 
 CD133+  Prostate and breast CSCs, 5-transmembrane domain cell surface glycopro-
tein, also a marker for neuron epithelial, hematopoietic and endothelial 
progenitor cells 
 1, 28 
 Stro1+CD105+CD44+  A surface marker for bone sarcoma  76 
 Nodal/activin  Knockdown or pharmacological inhibition of the nodal/activin receptor 
Alk4/7 in CSCs virtually abrogated their self-renewal capacity and in vivo 
tumorigenicity 
 51 
 Signaling
 pathways 
 Hedgehog  Being upregulated in many cancer types, inhibitors: GDC-0449, 
PF04449913, BMS-833923, IPI-926 and TAK-441 
 1, 16, 75 
 Wnt/-catenin  Be required for CSC self-renewal and tumor growth in different cancers, 
including CML and squamous cell carcinoma, inhibitors: PRI-724, WIF-1 
and telomerase 
 1, 16, 22 
 Notch  An important regulator in normal development, adult stem cell mainte-
nance, and tumorigenesis in multiple organs, inhibitors: RO4929097,
BMS-906024, IPI-926 and MK0752 
 1, 16 
 PI3K/Akt/PTEN/mTOR  Is deregulated in many tumors and used to preferentially target CSCs, in-
hibitors: temsirolimus, everolimus FDA-approved therapy for renal cell 
carcinoma 
 75 
 Niche  Angiogenesis (VEGF)  Inhibitor: bevacizumab results in a disruption of the CSC niche, depleted 
vasculature and a dramatic reduction in the number of CSCs in colon, 
breast and non-small-cell lung cancer 
 61 
 Hypoxia (HIF pathway)  Inhibitors: topotecan and digoxin have been approved to be clinically ap-
plied in ovarian, lung and cervical cancer 
 17 
 miRNAs  miR-200 family  The miR-200 family inhibits EMT and cancer cell migration by direct tar-
geting of E-cadherin transcriptional repressors ZEB1 and ZEB2 
 64 
 Let-7 family  Regulates BT-IC stem cell-like properties by silencing more than one target  77 
 miR-124  Targets laminin 1 and integrin 1; related to neuronal differentiation  66 
 miR-21  Suppresses the self-renewal of embryonic stem cells  78 
 AML = Acute myeloid leukemia; FDA = Food and Drug Administration; VEGF = vascular endothelial growth factor; HIF =
hypoxia-inducible factor; EMT = epithelial-mesenchymal transition; BT-IC = breast tumor-initiating cell. 
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CSCs  [3, 15, 59] . Thus, the difference in telomere length 
between normal (long) and cancer (short) stem cells 
could provide therapeutic selectivity  [15] .
 In a phase II clinical trial, telomerase peptide vacci-
nation using the telomerase peptide GV1001 after che-
moradiotherapy of non-small-cell lung cancer proved to 
increase the disease-free survival and was well tolerated. 
The majority of non-small-cell lung cancer patients were 
immunized and established a durable T-cell memory 
 [60] .
 Targeting CSC Survival Niches
 Targeting the CSC survival niche may disconnect in-
trinsic and extrinsic signals that maintain and govern 
CSCs in their division and differentiation. Both epitheli-
al-mesenchymal transition and tumor angiogenesis con-
tribute to microenvironments supporting enrichment of 
CSCs. Interestingly, CSCs in solid tumors are indeed con-
centrated around blood vessels depending in part on sig-
nals from endothelial cells  [17] . Therefore, antiangiogen-
ic therapies such as bevacizumab (antivascular endothe-
lial growth factor antibody) against metastatic colorectal 
cancer  [61] can be considered as a potential strategy to 
deplete the tumor from CSCs by compromising their 
niche.
 Hypoxia which has also been identified as CSC niche 
can drive tumor progression by triggering a set of adap-
tive transcriptional responses that regulate tumor angio-
genesis, metabolism, motility and survival  [62] . Interest-
ingly, direct or indirect targeting of hypoxia-inducible 
factors have proven to reduce the CSC-mediated tumor 
growth  [63] .
 Manipulation of MicroRNA Expression
 MicroRNAs (miRNAs) are small noncoding RNA 
molecules that can regulate gene expression by interact-
ing with multiple mRNAs inducing either suppression of 
translation or degradation of mRNA  [64] . miRNAs are 
often deregulated in various cancers and therefore offer 
therapeutic potential.
 In particular, epithelial mesenchymal transition is 
regulated by signals originating from the tumor micro-
environment which in turn modulate miRNA networks 
in CSC populations  [64] . The existence of multiple stem 
cell states suggests the necessity of developing therapeutic 
strategies capable of effectively targeting CSCs in all these 
different states  [65] . Since the CSC states are regulated by 
miRNAs, these small noncoding RNAs may be useful 
therapeutic agents to selectively target CSCs.
 Emerging evidence has indicated that plenty of spe-
cial miRNAs are physiologically required for stem cells. 
For example, miR-124 has shown to regulate both alter-
native splicing and the transcriptional network pro-
moting neuronal differentiation  [66] . Moreover, some
miRNAs are responsible for self-renewal and differentia-
tion by negatively regulating the expression of certain 
key genes in stem cells. In human embryonic stem cells, 
8 miRNA loci are located within a 700-bp region on 
chromosome 4, while another 4 miRNA loci are mapped 
within a 1,050-bp region on chromosome 19  [67] . Re-
cently, a study demonstrated that certain miRNAs that 
regulate the critical promoter of the stem cell self-renew-
al factor BMI-1 were downregulated in purified popula-
tions of normal mammary epithelial stem cells and 
breast CSCs  [64, 68] .
 The transcriptional repressor zinc-finger E-box bind-
ing homeobox 1 (ZEB1) is a crucial inducer of epithelial-
mesenchymal transition in various human tumors. ZEB1 
represses expression of miR-200c, miR-203 and miR-183, 
which drives the tumor-initiating properties of pancre-
atic and colorectal cancer cells by upregulating expres-
sion of stem cell factors Sox2 and Klf4  [69] . Therefore, the 
ZEB1-miR-200 feedback loop might form the basis of a 
promising treatment for solid tumors such as pancreatic 
cancer  [64] .
 How to Evaluate the Clinical Efficacy of
CSC-Targeted Therapy?
 In vitro preclinical models and in vivo xenotransplan-
tations have been initiated developing potential CSC-tar-
geting agents; however, accurate methods evaluating 
their future efficacy in a clinical setting are still a major 
challenge. Phase II trials are designed to assess the activ-
ity of new compounds using surrogate endpoints to de-
termine whether a phase III trial is warranted  [70] . Sur-
rogate markers for measuring CSC activity during and 
after therapy need to be established. Repetitive quantifi-
cation of in vitro clonogenic capability as surrogate mark-
er for CSC activity has been successfully correlated in 
multiple myeloma with progression-free survival and 
clinical relapse  [71] . The commonly accepted criterion for 
clinical efficacy is overall survival which can only be 
evaluated in prospective controlled phase III trials re-
quiring large numbers of patients and a long-term fol - 
low-up. So far, for acute myeloid leukemia and glioblas-
toma, a correlation between CSC burden at the time of 
diagnosis and clinical endpoints such as achievement of 
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remission and overall survival has been demonstrated in 
retrospective analyses  [18] .
 In the future, prospective clinical trials have to be de-
signed to evaluate the clinical efficacy of novel CSC-tar-
geted therapy in combination with critical surrogate 
markers to demonstrate changes in CSC activity.
 Conclusion
 Based on our current knowledge, various properties 
such as drug resistance as well as migratory and invasive 
potential are attributed to CSCs in addition to their de-
fining characteristics of self-renewal capacity and tumor-
igenicity.
 Still, the majority of current treatment modalities 
against cancer target the terminally differentiated cancer 
cells instead of the CSCs. Currently, there are already 
some potential anti-CSC agents in preclinical and clini-
cal trials including the notch inhibitors for glioblastoma 
and the telomerase peptide vaccination after chemora-
diotherapy of non-small-cell lung cancer  [58, 60] . While 
these are promising agents, the likelihood of clinical suc-
cess will depend on many aspects, including safety, trial 
design and rational endpoints. To demonstrate the effi-
cacy of CSC-targeted therapy for solid and hematopoi-
etic tumors, further research has to be performed to iden-
tify clinically relevant surrogate markers including e.g. 
frequency, localization and gene signatures of CSCs link-
ing them to clinical endpoints such as overall survival, 
disease-free survival and relapse-free survival.
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